Top 5 Target	Count

p38 MAPK(P38 mitogen-activated protein kinase)	4
CCNK(cyclin K)	2
TNF-α(Tumor necrosis factor α)	2
MNK1(MAP kinase-interacting serine/threonine-protein kinase MNK1)	2
FXR(Bile acid receptor FXR)	2

Drugs associated with Guangdong Pharmaceutical University

Salvianolic acid A

Target

STING x miR-204-5p

Mechanism

STING inhibitors [+2]

Active Org.

China Pharmaceutical University [+7]

Originator Org.

Chinese Academy of Medical Sciences

Active Indication

Acute Chest Syndrome [+9]

Inactive Indication

Angina Pectoris [+1]

Drug Highest PhasePhase 1

First Approval Ctry. / Loc.-

First Approval Date-

ZLY18

Target

GPR40 x PPARα x PPARγ x PPARδ

Mechanism

GPR40 agonists [+3]

Active Org.

Guangdong Pharmaceutical University

Originator Org.

Guangdong Pharmaceutical University

Active Indication

Metabolic Dysfunction Associated Steatohepatitis

Inactive Indication-

Drug Highest PhasePreclinical

First Approval Ctry. / Loc.-

First Approval Date-

Compound 3b(Guangdong Pharmaceutical University)

Target-

Mechanism-

Active Org.

Guangdong Pharmaceutical University

Originator Org.

Guangdong Pharmaceutical University

Active Indication

Melanoma

Inactive Indication-

Drug Highest PhasePreclinical

First Approval Ctry. / Loc.-

First Approval Date-

Clinical Trials associated with Guangdong Pharmaceutical University

ISRCTN13961960

/ Not yet recruitingNot ApplicableIIT

Effects of nurse-led online-offline collaborative peer-support on social participation among stroke patients: a randomised controlled trial

Start Date01 Oct 2026

Sponsor / Collaborator

Guangdong Pharmaceutical University

NCT07833423

/ Not yet recruitingNot Applicable

Efficacy of Temporal Interference-based Deep Brain Stimulation Combined With Conventional Rehabilitation Training for Lower Limb Motor Dysfunction After Stroke: A Prospective Randomized Controlled Clinical Trial

Stroke, as one of the most disabling neurological diseases worldwide, causes significant functional impairments in the lower limbs, severely affecting the quality of life of patients. Traditional neuroregulation techniques such as transcranial magnetic stimulation (TMS) and transcranial direct current/alternating current stimulation (tDCS/tACS) can only intervene in the cerebral cortex. Deep brain stimulation (DBS), which requires invasive craniotomy to implant electrodes and has certain risks, is difficult to fully meet the rehabilitation needs of patients. These treatment methods are insufficient. Transcranial Temporal Interference (TI) Stimulation, as a new non-invasive neuroregulation technology, generates low-frequency envelope signals through high-frequency electric fields to achieve precise stimulation of deep brain tissues, providing a new direction for the treatment of stroke. This study is a clinical research to explore the efficacy of TI technology in the treatment of lower limb dysfunction in stroke, aiming to expand the clinical practice of TI technology in the field of stroke rehabilitation and provide theoretical support and practical guidance for the transformation and application of TI technology.

Start Date01 Oct 2026

Sponsor / Collaborator

Guangdong Pharmaceutical University

ChiCTR2600120356

/ RecruitingNot ApplicableIIT

A Mixed-Methods Study on the Current Status and Influencing Factors of Self-Advocacy among Maintenance Hemodialysis Patients

Start Date01 Mar 2026

Sponsor / Collaborator

Guangdong Pharmaceutical University

[+1]

100 Clinical Results associated with Guangdong Pharmaceutical University

0 Patents (Medical) associated with Guangdong Pharmaceutical University

4,292

Literatures (Medical) associated with Guangdong Pharmaceutical University

01 Feb 2027·Biomaterials advances

Novel dissolving microneedles incorporating natural carrier-free self-assembled nanoparticles synergized with electroacupuncture for diabetic wound healing

Article

Author: Zhao, Dongyu ; Huo, Huanglin ; Zhang, Jinyi ; Zeng, Menglan ; Zeng, Huicong ; Li, Bo ; Li, Menghan ; Zhou, Qian ; Zeng, Youyan

Diabetic wounds (DW) are one of the most common complications of diabetes with complex pathogenesis, causing high morbidity and disability. Conventional therapies fail to resolve multiple obstacles to DW healing, urgently requiring efficient and safe novel interventions. Compounds from medicine and food homology substances have attracted widespread attention owing to their superior biosafety and diverse pharmacological activities. Herein, carrier-free APC and GQS nanoparticles were manufactured separately via self-assembly using medicine and food homology bioactive components, including astragalus polysaccharide, chlorogenic acid, quercetin, β-sitosterol, and glycyrrhizin acid. Subsequently, dissolvable APC@GQS@MNs co-loaded with APC and GQS were constructed using polyvinylpyrrolidone, hyaluronic acid, and aloe vera as matrix materials. Physicochemical characterization confirmed that APC@GQS@MNs have a well-defined conical morphology, satisfactory mechanical strength, and favorable skin penetration. The APC@GQS@MNs also enabled efficient selective scavenging of cytotoxic reactive oxygen species (ROS), while physiological ROS were less affected. Meanwhile, APC@GQS@MNs exhibited favorable biocompatibility, reduced intracellular ROS levels, ameliorated oxidative stress-induced damage to cell proliferation, migration and tube formation, promoted M1 to M2 macrophage polarization, and effectively inhibited the growth and biofilm formation of Staphylococcus aureus and Escherichia coli. In vivo results showed that APC@GQS@MNs promoted collagen deposition, re-epithelialization, and reduced local inflammatory infiltration in DW by upregulating CD31, CD163, IL-10 and suppressing iNOS, NF-κB, and TNF-α signaling. Notably, APC@GQS@MNs combined with electroacupuncture exerted synergistic effects, which further ameliorated the wound microenvironment and markedly accelerated wound healing and tissue regeneration. Such synergistic therapy modulates local wound states and inflammatory responses, laying a promising foundation for the management of DW.

01 Feb 2027·JOURNAL OF ETHNOPHARMACOLOGY

Icaritin ameliorates diabetes-associated cognitive dysfunction by attenuating ferroptosis through PPARα/CPT1A-associated fatty acid oxidative regulation

Article

Author: Wang, Rongrong ; Qiu, Yunshun ; Han, Yanzhong ; Liang, Zixia ; Pan, Chenglong ; Zhang, Guimin ; Li, Meijia ; Li, Shirong ; Wang, Ying ; Jiao, Xu ; Yang, Wenlong ; Lu, Xiaoyan ; Wang, Min ; Yao, Jingchun

ETHNOPHARMACOLOGICAL RELEVANCE:

Diabetes-associated cognitive dysfunction (DACD) is a neurological complication of diabetes characterized by impaired learning and memory. Epimedium is a traditional Chinese medicinal herb used for conditions associated with diabetes and cognitive decline. Icaritin (Y003), a bioactive prenylated flavonoid derived from Epimedium and an active metabolite of flavonoid glycosides such as icariin, has shown glucose-lowering and neuroprotective effects. However, its effects on DACD and underlying mechanisms remain unclear.

AIM OF THE STUDY:

This study aimed to explore the efficacy and mechanisms of Y003 against DACD in vivo and in vitro.

MATERIALS AND METHODS:

A DACD mouse model was established using HFD/STZ and treated orally with Y003. Cognitive function, metabolic disturbances, tissue pathology, gut microbiota, metabolomics, brain fatty acid profiles, protein expression, and ferroptosis-related indices were evaluated using complementary behavioral, biochemical, histological, multi-omics, and molecular analyses. In parallel, HG/PA-treated HT22 cells were used to evaluate Y003 effects, with ferrostatin-1 (Fer-1), GW6471(GW), and etomoxir (ETO) used for pharmacological validation of ferroptosis and PPARα/CPT1-associated regulation.

RESULTS:

Y003 markedly ameliorated glucose and lipid metabolic disturbances, cognitive deficits, and hippocampal neuronal injury in DACD mice. Multi-omics analyses revealed coordinated alterations in gut microbiota composition, peripheral metabolism, and medium- and long-chain fatty acid profiles in brain tissue, suggesting microbiota-gut-brain axis-associated metabolic remodeling. In brain tissue, Y003 restored PPARα and CPT1A expression and CPT1 activity while reducing lipid peroxidation and iron accumulation and improving antioxidant defense, consistent with attenuation of ferroptosis-related injury. In HG/PA-treated HT22 cells, Y003 improved cell viability and reduced lipid ROS accumulation. Fer-1 produced similar protective effects, whereas GW and ETO partially attenuated Y003-mediated protection. These findings suggest that the protective effects of Y003 are associated with restoration of PPARα/CPT1A-associated fatty acid oxidative capacity and attenuation of ferroptosis-related injury.

CONCLUSION:

Y003 may ameliorate metabolic disturbances and cognitive dysfunction in DACD through microbiota-gut-brain axis-associated fatty acid metabolic remodeling and restoration of PPARα/CPT1A-associated fatty acid oxidative capacity, providing a scientific basis for further preclinical and clinical investigation.

01 Feb 2027·COMPUTATIONAL BIOLOGY AND CHEMISTRY

Potential mechanisms linking polyethylene terephthalate microplastic-associated exposure factors to abnormal biomineralization

Article

Author: Zheng, Xiaopeng ; Liu, Chunyu ; Lu, Junxuan ; Yu, Bangxian ; Zhang, Fuxiang ; Jiang, Yong ; Sun, Xinyuan ; Shang, Zhiqun ; Zhang, Haiyang

Microplastic exposure has raised health concerns. However, whether degradation products and migrants associated with polyethylene terephthalate microplastics (PET-MPs) contribute to diseases associated with abnormal biomineralization remains unclear. Here, terephthalic acid (TPA), ethylene glycol (EG), mono(2-hydroxyethyl) terephthalate (MHET), bis(2-hydroxyethyl) terephthalate (BHET), PET cyclic trimer, acetaldehyde, and antimony trioxide (Sb₂O₃) were defined as PET-MP-associated exposure factors (PAEFs). This study establishes a cross-disease biomineralization framework separates PET-MP particle exposure from associated small-molecule chemical exposure. Computational toxicology, target prediction, transcriptomics, network analysis, functional enrichment, molecular docking, and molecular dynamics (MD) simulations were integrated to assess their potential links with kidney stone disease (KSD), vascular calcification (VC), and myositis ossificans (MO). Toxicity predictions revealed heterogeneity among PAEFs in physicochemical properties, barrier permeability, and toxicological endpoints. Integration of 1747 PAEF targets with disease datasets identified 217, 101, and 25 candidate targets for KSD, VC, and MO, respectively, prioritizing 33, 12, and 7 core proteins through protein-protein interaction analysis. Functional enrichment indicated convergence on inflammation, oxidative stress, mitochondrial dysfunction, extracellular matrix remodeling, and osteogenic signaling. Molecular docking identified several PAEF-core protein pairs with binding energies below -7 kcal/mol, while TPA, MHET, BHET, and PET cyclic trimer showed broad predicted binding. Triplicate MD simulations showed mean protein and ligand root-mean-square deviations (RMSDs) of 2.06 and 3.77 Å, respectively, and 2.28 hydrogen bonds on average, supporting stable binding after ligand adjustment. These findings suggest that PAEFs may contribute to abnormal biomineralization through multi-target and multi-pathway mechanisms, providing a basis for exposure risk assessment and mechanistic validation.

News (Medical) associated with Guangdong Pharmaceutical University

08 Jan 2024

·www.biospace.com

YS Biopharma Announces Changes to its Board Committees - Jan 08, 2024

GAITHERSBURG, Md., Jan. 8, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that the Company's Board of Directors (the "Board") has approved Ms. Rui Yu as the new Chairperson of its Audit Committee, as a member of its Compensation Committee, and as a member of the Nominating and Corporate Governance Committee on January 7, 2024 (Beijing Time), with immediate effect. Ms. Yu currently serves as a partner at Oceanpine Capital, a position she has held since 2021. Prior to that, she served as a managing director at China Renaissance Group and vice president and head of China healthcare research at Gerson Lehman Group. Ms. Yu received her Bachelor of Science degree from Guangdong Pharmaceutical University, her Master of Science degree from the University of Missouri School of Medicine, and her MBA from the University of Chicago Booth School of Business with concentrations in finance, accounting and entrepreneurship. Accordingly, the membership of each Board Committee will be as follows: Audit Committee Rui Yu (Chairperson), Viren Mehta, and Shaojing Tong Compensation Committee Viren Mehta (Chairperson), Ajit Shetty, Shaojing Tong, and Rui Yu Nominating and Corporate Governance Committee Ajit Shetty (Chairperson), Viren Mehta, Rui Yu, and Yi Zhang About YS Biopharma YS Biopharma is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and commercializing new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA® immunomodulating technology platform and a series of preventive and therapeutic biologics with a potential for improved Rabies, Coronavirus, Hepatitis B, Influenza, and Shingles vaccines. YS Biopharma operates in China, the United States, Singapore and the Philippines, and is led by a management team that combines rich local expertise and global experience in the bio-pharmaceutical industry. For more information, please visit investor.ysbiopharm.com. Investor Relations Contact Robin Yang Partner, ICR, LLC Tel: +1 (212) 537-4035 Email: YSBiopharma.IR@icrinc.com View original content to download multimedia: SOURCE YS Biopharma Co., Ltd. Company Codes: NASDAQ-NMS:YS

Executive ChangeVaccine

100 Deals associated with Guangdong Pharmaceutical University

100 Translational Medicine associated with Guangdong Pharmaceutical University

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 04 Nov 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

Preclinical

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Iridium(III) complexes 2b(Guangdong Pharmaceutical University)	Colorectal Cancer More	Preclinical
Iridium(III) complexes 2c(Guangdong Pharmaceutical University)	Colorectal Cancer More	Preclinical
Iridium(III) complexes 2a(Guangdong Pharmaceutical University)	Colorectal Cancer More	Preclinical
CXCR3-expressing EGFR-targeted CAR-NK(Guangdong Pharmaceutical University) ( CXCR3 x EGFR )	Non-Small Cell Lung Cancer More	Preclinical
SPS-SeS2 NPs	Dandruff More	Preclinical

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis